Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Huang, Lu; Liao, Zhiwei; Liu, Zhixi; Chen, Yan; Huang, Tingwenli; Xiao, Hongtao

doi:10.3389/fphar.2022.900825

Cited by 6 publications

(9 citation statements)

References 126 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Physical methods including electroporation and microinjection are regularly used to delivery CRISPR components in vivo studies. Microinjection has the limitations of high costs and poor efficiency (Huang et al, 2022). However, an electroporation-based strategy transports Cas9/sgRNA ribonucleoproteins (RNPs) into mouse fertilized eggs with 100% efficiency, realizing extremely efficient gene editing in vivo (Chen et al, 2016).…”

Section: Delivery Methods Of Crispr Componentsmentioning

confidence: 99%

“…Due to their efficient infection ability towards the lung epithelium in adult mice, ADVs are regarded as an ideal method for constructing the aforementioned lung cancer model harboring EML4-ALK inversion (Maddalo et al, 2014). Adenoassociated viruses (AAVs) are less immunogenic compared to other viral vectors, exhibiting clinical therapeutic promise (Huang et al, 2022).…”

Section: Delivery Methods Of Crispr Componentsmentioning

confidence: 99%

See 1 more Smart Citation

Applications and advancements of CRISPR-Cas in the treatment of lung cancer

Lei,

Ju,

Peng

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Lung cancer is one of the most malignant diseases and a major contributor to cancer-related deaths worldwide due to the deficiency of early diagnosis and effective therapy that are of great importance for patient prognosis and quality of life. Over the past decade, the advent of clustered regularly interspaced short palindromic repeats/CRISPR associated protein (CRISPR/Cas) system has significantly propelled the progress of both fundamental research and clinical trials of lung cancer. In this review, we review the current applications of the CRISPR/Cas system in diagnosis, target identification, and treatment resistance of lung cancer. Furthermore, we summarize the development of lung cancer animal models and delivery methods based on CRISPR system, providing novel insights into clinical diagnosis and treatment strategies of lung cancer.

show abstract

Section: Delivery Methods Of Crispr Componentsmentioning

confidence: 99%

Section: Delivery Methods Of Crispr Componentsmentioning

confidence: 99%

Applications and advancements of CRISPR-Cas in the treatment of lung cancer

Lei,

Ju,

Peng

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Interestingly, targeted genetic changes linked to resistance mechanisms have been identified by CRISPR/Cas9 gene editing, which shows potential for treating drug resistance in respiratory diseases [ 158 ]. Clinical trials are underway to evaluate the safety and efficacy of CRISPR/Cas9 gene editing in overcoming drug resistance in respiratory disorders.…”

Section: Clinical Trials Of Crispr/cas9 Gene Editing For Respiratory ...mentioning

confidence: 99%

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen,

Najmadden,

Abdullah

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Respiratory disorders are among the conditions that affect the respiratory system. The healthcare sector faces challenges due to the emergence of drug resistance to prescribed medications for these illnesses. However, there is a technology called CRISPR/Cas9, which uses RNA to guide DNA targeting. This technology has revolutionized our ability to manipulate and visualize the genome, leading to advancements in research and treatment development. It can effectively reverse epigenetic alterations that contribute to drug resistance. Some studies focused on health have shown that targeting genes using CRISPR/Cas9 can be challenging when it comes to reducing drug resistance in patients with respiratory disorders. Nevertheless, it is important to acknowledge the limitations of this technology, such as off-target effects, immune system reactions to Cas9, and challenges associated with delivery methods. Despite these limitations, this review aims to provide knowledge about CRISPR/Cas9 genome editing tools and explore how they can help overcome resistance in patients with respiratory disorders. Additionally, this study discusses concerns related to applications of CRISPR and provides an overview of successful clinical trial studies.

show abstract

“…Lung cancer is a complex disease that manifests in two primary forms: small-cell lung cancer and non-small-cell lung cancer [ 206 ]. Lung cancer has been identified as the second most diagnosed type of tumor, causing 1.8 million cancer-induced deaths [ 207 ].…”

Section: Crispr/cas-based Gene Therapies and Therapeutic Applicationsmentioning

confidence: 99%

“…Lung cancer has been identified as the second most diagnosed type of tumor, causing 1.8 million cancer-induced deaths [ 207 ]. Since cancer drug resistance has been the main culprit in providing relief to lung cancer patients, CRISPR techniques have offered a glimpse of hope for a better quality of life [ 206 ].…”

Section: Crispr/cas-based Gene Therapies and Therapeutic Applicationsmentioning

confidence: 99%

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Banda,

Impomeni,

Singh

et al. 2024

Vaccines

View full text Add to dashboard Cite

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated enzyme-CAS holds great promise for treating many uncured human diseases and illnesses by precisely correcting harmful point mutations and disrupting disease-causing genes. The recent Food and Drug Association (FDA) approval of the first CRISPR-based gene therapy for sickle cell anemia marks the beginning of a new era in gene editing. However, delivering CRISPR specifically into diseased cells in vivo is a significant challenge and an area of intense research. The identification of new CRISPR/Cas variants, particularly ultra-compact CAS systems with robust gene editing activities, paves the way for the low-capacity delivery vectors to be used in gene therapies. CRISPR/Cas technology has evolved beyond editing DNA to cover a wide spectrum of functionalities, including RNA targeting, disease diagnosis, transcriptional/epigenetic regulation, chromatin imaging, high-throughput screening, and new disease modeling. CRISPR/Cas can be used to engineer B-cells to produce potent antibodies for more effective vaccines and enhance CAR T-cells for the more precise and efficient targeting of tumor cells. However, CRISPR/Cas technology has challenges, including off-target effects, toxicity, immune responses, and inadequate tissue-specific delivery. Overcoming these challenges necessitates the development of a more effective and specific CRISPR/Cas delivery system. This entails strategically utilizing specific gRNAs in conjunction with robust CRISPR/Cas variants to mitigate off-target effects. This review seeks to delve into the intricacies of the CRISPR/Cas mechanism, explore progress in gene therapies, evaluate gene delivery systems, highlight limitations, outline necessary precautions, and scrutinize the ethical considerations associated with its application.

show abstract

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Cited by 6 publications

References 126 publications

Applications and advancements of CRISPR-Cas in the treatment of lung cancer

Applications and advancements of CRISPR-Cas in the treatment of lung cancer

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Contact Info

Product

Resources

About